Pharming Group N.V. (PHAR) is actively transforming its business model, moving from a focus on a single product to becoming a diverse entity in the rare disease sector. This evolution is driven by the promising expansion of its Joenja franchise and the progression of its clinical development programs. Despite a slight dip in overall revenue, the company's leadership highlighted the robust performance of Joenja and the significant potential within its development pipeline, emphasizing a strategic approach to managing its portfolio and capital allocation.
Pharming Group's Financial and Operational Insights from Q2 2026
On Thursday, July 30, 2026, at 7:30 a.m. ET, Pharming Group N.V. held its second-quarter 2026 earnings call, featuring key executives including Chief Executive Officer Fabrice Chouraqui, Chief Commercial Officer Leverne Marsh, Chief Medical Officer Anurag Relan, and Chief Financial Officer Kenneth Lynard. The discussion centered on the company's financial performance, strategic shifts, and future growth drivers.
The company reported total revenue of $90.2 million, marking a 3% year-over-year decrease. This decline was primarily attributed to a 10% drop in RUCONEST revenue, which totaled $72.3 million. Factors contributing to this reduction included increased competition in the U.S. market, a planned withdrawal from certain international markets, and a temporary normalization of inventory levels. However, RUCONEST demonstrated resilience, with its active patient base remaining at 93% of the previous year's level, even a year after a competing oral on-demand treatment was introduced. New patient enrollments for RUCONEST saw a notable increase to 84 in the second quarter, up from approximately 50 in the first quarter of 2026, indicating sustained physician confidence in the treatment.
In contrast, Joenja (leniolisib) showed impressive growth, with revenue surging by 40% year-over-year to $17.9 million. U.S. revenue for Joenja grew by 31% to $15.4 million, driven by an increase in new patient starts. International revenue for Joenja experienced an even more dramatic rise of 150%, reaching $2.5 million, reflecting accelerating commercial momentum, particularly in Europe. The company identified 132 U.S. patients on paid Joenja therapy and 298 identified APDS patients in the U.S., including 60 pediatric patients aged four to eleven, representing a crucial future growth segment. Furthermore, 387 potentially eligible APDS patients were identified across eight core international markets, with a launch in Japan anticipated in August.
Pharming revised its full-year revenue guidance to $375 million-$395 million, a reduction of $30 million from the prior outlook, reflecting the evolving hereditary angioedema (HAE) market dynamics. Concurrently, full-year operating expense guidance was lowered by $15 million to $315 million-$320 million, thanks to structural headcount reductions and a disciplined capital allocation strategy. The company also reported an operating cash outflow of $9.7 million for the quarter, largely due to changes in net working capital and a strategic inventory build. As of June 30, 2026, cash and marketable securities stood at $159.5 million, deemed sufficient to fund current development activities.
From a clinical development perspective, Chief Medical Officer Anurag Relan highlighted the significant potential of leniolisib beyond APDS, particularly in common variable immunodeficiency (CVID), which represents a patient population up to 40 times larger than APDS. Top-line results from two Phase II studies in CVID and other genetically defined primary immunodeficiencies (PIDs) are expected in the fourth quarter of 2026. The company also filed a supplemental New Drug Application (sNDA) for lower 20 mg and 30 mg doses of Joenja for pediatric patients in the U.S.
Leverne Marsh discussed the commercial expansion of Joenja, with a successful launch in Germany and upcoming launch in Japan. The company continues to invest in patient identification, genetic testing, and the reclassification of Variants of Uncertain Significance (VUSs) to drive further growth.
Kenneth Lynard elaborated on the financial results, noting that adjusted operating profit was positive despite lower revenues and increased R&D investments. He also addressed a $4.9 million manufacturing inventory impairment related to RUCONEST, which is currently under review.
Reflections on Pharming Group's Strategic Trajectory
The latest earnings call from Pharming Group paints a clear picture of a company navigating market challenges while aggressively pursuing diversification and growth. The resilience of RUCONEST, despite competitive pressures, underscores its established value in the HAE market, acting as a stable revenue generator. However, the true beacon of future growth appears to be Joenja, with its strong commercial performance and the expansive potential in broader immunological indications like CVID. The strategic reduction in operating expenses, coupled with continued investment in high-potential R&D, demonstrates a pragmatic approach to ensuring long-term sustainability and value creation. The emphasis on global expansion and pediatric indications for Joenja, alongside the ongoing clinical trials for leniolisib, suggests a robust pipeline that could significantly transform Pharming's market position. As a stakeholder, observing the balance between maintaining core product stability and driving innovative expansion is key. The anticipated results from the Phase II studies in CVID will be a critical inflection point, potentially unlocking substantial new markets and reinforcing Pharming's ambition to become a leading global rare disease company.